Table 1 Baseline characteristics, symptoms, and signs
| Â | Primary Tumor (n = 73) | 1st Recurrence (n = 28) | p |
|---|---|---|---|
Gender | Â | Â | 0.267 |
   Male | 39(53%) | 11(39%) |  |
   Female | 34(47%) | 17(61%) |  |
Age | Â | Â | Â |
   Mean years, sd | 58.0 ± 15.0 | 55.1 ± 12.8 | 0.365 |
   Median | 60.0 | 56.0 |  |
   Median 25% | 50.0 | 45.5 |  |
   Median 75% | 68.0 | 61.5 |  |
Analgetics* | Â | Â | 0.211 |
   None | 54 (75%) | 16 (59%) |  |
   Non-opioids | 16 (22%) | 9 (33%) |  |
   Opioids | 2 (3%) | 2 (7%) |  |
Enlarged Abdomen* | Â | Â | 0.596 |
   No | 57 (79%) | 20 (74%) |  |
   Yes | 15 (21%) | 7 (26%) |  |
Bleeding* | Â | Â | 0.126 |
   No | 50 (69%) | 25 (93%) |  |
   Intraabdominal | 5 (7%) | 0 |  |
   Upper GI | 5 (7%) | 0 |  |
   Lower GI | 12 (17%) | 2 (7%) |  |
Obstruction* | Â | Â | 1.000 |
   No | 60 (83%) | 23 (85%) |  |
   Postprandial pain | 7 (10%) | 2 (7%) |  |
   Ileus | 5 (7%) | 2 (7%) |  |
Palpable abdominal mass* | Â | Â | 0.647 |
   No | 29 (40%) | 9 (32%) |  |
   Yes | 43 (59%) | 17 (61%) |  |
Metastases* | Â | Â | Â |
   No | 69 (95%) | 20 (71%) | 0.010 |
   Yes | 3 (4%) | 6 (21%) |  |